Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company powering precision proteomics to enable the earliest detection of disease, are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomics biomarkers.

Cleveland Clinic Receives $12 Million NIH Grant to Investigate Use of Inflammatory Cytokines in Personalized Cancer Treatments

Cleveland Clinic’s Lerner Research Institute was awarded a five-year $12 million grant by the National Cancer Institute, part of the National Institutes of Health, to define how cytokines – proteins produced during immune response – regulate inflammation and interact with cells and molecules surrounding tumors.

Reducing lung transplant rejection aim of clinical trial funded with $22 million grant

Physicians at Washington University School of Medicine in St. Louis and Massachusetts General Hospital/Harvard Medical School in Boston have received a seven-year, $22 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to help lead a multicenter clinical trial evaluating whether a novel immunosuppressant can reduce the risk of organ rejection after a lung transplant.

Blood-flow Restriction Training Delay the Progression of Chronic Kidney Disease

Chronic kidney disease (CKD) is recognized as a public health problem, affecting more than 15% of the population. Although CKD can drastically impair health, it is rarely diagnosed early due to its silent revelation. Identifying and proposing treatments to attenuate…

CHOP Researchers Identify Lab Profiles that Differentiate MIS-C from COVID-19 in Children

Researchers from Children’s Hospital of Philadelphia (CHOP) report important data that differentiate MIS-C from severe COVID-19 in children and suggest that MIS-C is a post-infectious syndrome related to COVID-19 but distinct from KD. The findings were published today in The Journal of Clinical Investigation.

Moffitt Researchers Identify Factors to Predict Severe Toxicities in CAR T Patients

In a new study published in Clinical Cancer Research, Moffitt Cancer Center researchers identify possible factors that could help physicians know if patients are at higher risk for severe adverse events before they receive CAR T therapy.